<--GAT-->
Clinical Topics

Better Survival for NSCLC Patients Treated by Military Medicine

by U.S. Medicine

November 29, 2018

BETHESDA, MD—Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

That was the question examined in a new study published in Cancer Epidemiology, Biomarkers & Prevention. Survival of NSCLC patients treated within the MHS was compared to the U.S. general population.1

The study was led by researchers from the John P. Murtha Cancer Center, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center. MHS data for the study were from the DoD’s Automated Central Tumor Registry (ACTUR), while data for the general population came from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

The focus was on NSCLC patients diagnosed between Jan. 1, 1987, and Dec. 31, 2012, in ACTUR and a sample of SEER patients who were matched to the ACTUR patients on age group, sex, race and year of diagnosis group with a matching ratio of 1:4. Follow-up continued through Dec. 31, 2013.

Ultimately, 16,257 NSCLC patients were identified from ACTUR ,and 65,028 matched patients from SEER.

Results indicated that, Compared with SEER patients, ACTUR patients had significantly better overall survival (log-rank P < 0.001). The better overall survival among the ACTUR patients remained after adjustment for potential confounders (HR = 0.78, 95% confidence interval, 0.76-0.81).

Researchers emphasized that the survival advantage of the ACTUR patients was present regardless of cancer stage, grade, age group, sex or race.

“The MHS’s universal care and lung cancer care programs may have translated into improved survival among NSCLC patients,” study authors concluded, pointing out that their results confirms that NSCLC patients with universal care access have better outcomes.

1. Lin J, Kamamia C, Brown D, Shao S, McGlynn KA, Nations JA, Carter CA, Shriver CD, Zhu K. Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):673-679. doi: 10.1158/1055-9965.EPI-17-0822.



Related Articles

Combat, Not Deployment, Appears to Increase Risk of New-Onset Asthma

BETHESDA, MD—Many reports have suggested that servicemembers who deployed to Iraq and Afghanistan developed respiratory illnesses at higher-than-expected rates, but study results looking at increased rates of asthma have been mixed. A new study by... View Article

VA Continues Efforts to Reduce Drug Diversion; Focuses on Opiates

WASHINGTON—In the past two years, the VA has implemented a nine-step process to minimize drug diversion, but cases continue to slip through. In December 2018, the VA’s Office of the Inspector General reported two instances... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.

Oncology

Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up